www.fdanews.com/articles/195823-seqiruss-pandemic-influenza-vaccine-gets-fda-approval
Seqirus’s Pandemic Influenza Vaccine Gets FDA Approval
February 10, 2020
The FDA approved Seqirus’ Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to protect individuals six months or older against influenza A (H5N1).
The novel vaccine combines MF59 adjuvant and cell-based antigen manufacturing. The product is designed to be stockpiled for use by first responders in case of pandemic.
The approval makes Audenz the first adjuvanted, cell-based influenza vaccine designed to protect against influenza A in the event of a pandemic.